Special Husbandry Requirements: Describe any special requirements your animals have with respect to food, water, temperature, humidity, light cycles, caging type, bedding, or any other conditions of husbandry.
The animals need to be caged in BSL2 isolation after SIV infection.
Biscuit intake of each animal should be noted. 
Summary of Procedures:
a) Briefly describe the overall intent of the study. Include in your description a statement of your hypothesis, the objectives and significance of the study. Your target audience is a faculty member from a discipline unrelated to yours. Do not use jargon.
The objective of these experiments is to evaluate the interaction between the cyclical disturbances of regulatory function induced by chronic administration of opioids and the development of a simian AIDS-like syndrome. In this proposal, induced opioid dependency and induced simian AIDS in rhesus monkeys will be used as a model system to study opioid dependency in human AIDS patients. The progression of the viremia involving the loss of antiviral and antibacterial endogenous defenses as well as cell-mediated immune mechanisms will be monitored. In addition, the interaction between the viremia and opportunistic bacteremia/infections will be characterized in an effort to further understand the molecular mechanisms involved in AIDS.
b) Procedures employed in this project:
Please check the appropriate boxes if any of these procedures will be employed in your project: Animals will be trained to accept injections and to submit to the drawing of venous blood. We will treat the animals (monkeys) with opioids (I.M./subcutaneous injections of morphine or methadone, 0.7 ml volume) and then experimentally infect the animals with SIVmac239. Saline-injected and SIVmac239-infected monkeys will serve as a control group. Six animals in each group and a total of 18 animals will be used. All animals will receive three injections (at 7 a.m., 3 p.m. and 11 p.m.) per day and seven days a week. The injection will be given throughout the project. Before the opioid studies, it will take one month of saline injections to establish baseline measurements. Morphine or methadone treatment will begin at 1 mg/kg per injection and increase to a stabilization dose of 5 mg/kg per injection (a total of three months is needed for establishing opioid dependency). The animals will imbibe water from the CRPRC's Automatic Lixit Device and will be weighed once per week. Blood samples will be drawn at periodic intervals (normally, 6-15ml blood per animal every 3-4 weeks.) Aliquots will be evaluated for polymorphonuclear cells (PMN) and T-lymphocyte activity and the expression of opioid receptors. At selected intervals (one to two times a year), estimates on the levels of circulating opioids in the blood samples drawn will be made (0.5 to 1 ml is enough for this purpose). Behavioral ratings will be made using our previously published rating scales (see Appendix I) which was originally developed at the University of Michigan for the description of the effect of opioids on M. mullata. Briefly speaking, the cage behavior of male rhesus monkeys will be annotated using bar codes to describe as many aspects of the behavior of monkeys as possible. The observer is prompted by a program on a notebook computer. The observer selects the appropriate bar code and strokes the code with the input wand. The data are stored in the notebook computer until the end of the observation session. The notebook computer is then attached to a larger laboratory computer and the data transferred from the notebook computer to the laboratory computer. Behavioral profiles will be gathered two times a week throughout the project, each time for 30 minutes before and after the 3 p.m. injection and during feeding, blood drawing procedures and later on after SIVmac infections. Approximately three months are needed to establish opioid dependency. When signs of stability of the opioid dependency emerge, animals will be inoculated via the intravenous route with SIVmac239 (1.58x10 3 rhesus monkey infectious dosage 50 /animal). These signs include lack of constant weight gains, change of normal eating behaviors and sleep patterns, and reduction in sexual activities (Masturbating behavior decreases in incidence.) Morphine dependency can easily be detected when morphine injection was inadvertently missed and withdrawl syndrome -nausea, vomiting, sweating, gooseflesh (goose pimples), diarrhea, tremor, chills, and fever -occurs. SIV viremia will be followed by assaying SIV P27 core antigen of infected monkey plasma, co-cultivation of monkey PBMC (peripheral blood mononuclear cells) with CEM x174 cells to isolate SIV virus, and by determining the viral sequence in monkey PBMC using the polymerase chain reaction (PCR). Evaluation of PMN chemotaxis/phagocytosis activities, Tlymphocyte functions (CD4+ cell proliferation, CD8+ cell-mediated antiviral activities) and humoral immune response (anti-SIV antibody formation) of the infected animals will be studied. All these assays/studies have previously been performed in our laboratory. Clinical signs of smian AIDS may include generalized lymphadenopathy, splenomegaly, neutropenia, lymphopenia or histologic lymphoid depletion, weight loss greater than 10%, anemia, abnormal peripheral blood monocytes, bone marrow hyperplasia, persistent diarrhea, chronic skin infections, opportunistic infections and tumor formation. The average life expectancy for SIV-infected monkeys is 18-20 months. However, other factors such as drug treatment, weekend schedules of feeding and care, emergence of intercurrent diseases transmitted by the colony and procedures (human handling), etc., will also affect the life expectancy of the experimental animals. Nevertheless, by serial monitoring of each treatment group changes may be recognized and used to verify the validity of our experimental data. With respect to those animals survived from the SIVmac239 infection, they will be maintained in the colony for long-term survivor studies.
The proposed increment of drug dosages (0 to 5 mg/kg) is according to blood levels and comportment (behavior) changes established by previous studies over years here and elsewhere by others. By the proposed procedure of a gradual increase of opioid dose to establish opioid dependency, there will not be any incident of opioid overdose.
All monkeys will initially be injected I.M./subcutaneously with saline (0.9% NaCl, 0.7 ml,) 3 times a day. Sites of I.M./S.C. injections will be rotated often to alleviate muscle sores. The monkeys to be used as control monkeys will continue to receive saline at the times when the treatment groups receive opioids. The opioid treatment groups will receive morphine or methadone 3 times daily, starting at 1 mg/kg per administration and increasing to 3 mg/kg and a maximum of 5 mg/kg per administration. All 18 animals to be used in our study will be subjected to SIVmac239 infection. Pre-selection of these 18 animals is based upon serological studies which show that the animals have not previously been exposed to SRV, STLV-1 or SIV. Animals will be selected and placed into three different experimental groups, based upon their body weights and other criteria such as our pre-infection T-cell and PMN functional studies. Each group will consist of heterogeneous populations of animals with regard to these criteria. With respect to the numbers (6/group for a total of 18) of animals used, statistical considerations have been applied. The proposed study uses primates as the experimental subjects. When small laboratory species are used, even quite subtle differences in activity and behavior may often be detected by increasing the numbers of animals and thus decreasing within-group variability by a factor roughly proportional to the square root of the increase in group size. However, a considerable increase in group-size is impractical with larger species particularly when those species are primates, since both the cost of purchase, care, and experimental manpower set limits on animal numbers. We use six (6) animals per treatment group and 18 animals per experiment (three treatment groups: saline, morphine and methadone). Given that two independent groups of subjects are to be compared on the frequency of occurrence of a particular all-or-nothing factor (e.g. death or survival, presence or absence of a symptom), and with each group (sample) being given a different treatment (e.g. infected or non-infected, control or drugtreated), it can be shown by the application of Fisher's exact probability test to hypothetical models that significant data can be obtained if the sample size used is 6, no matter how extreme the differences are between expected (control) and observed (treated) frequencies. In any event that the opioid-dependent animals need to be released from the project, a detoxification procedure will be used. Detoxification by a gradual, progressive and slow reduction of opioid dose (5 mg/kg→3 mg/kg→1 mg/kg→0 mg/kg) will not induce withdrawal syndrome in the animals. This procedure is clinically used in reducing the opioid dependency of human addicts.
d) Study Groups and Numbers:
Define, in the form of a table, the numbers of animals to be used in each experimental group described above. The table may be presented on a separate page as an attachment to this protocol if you prefer. The Normal format should be three columns: Study Group, Procedure, Number of animals. The number of rows should follow from the number of study groups; you may add as many rows as you require. The chart must fully account for the number of animals you intend to use under this protocol. Assign each group to an invasiveness category according to the chart below.
Group
Procedures / Drugs Number of Animals Category Further descriptions of these categories are included in the instructions following this document.
e) Rationale for species and numbers: How did you determine that the species choice was appropriate and the number of animals in the groups above was the minimum number necessary to achieve sound scientific results?
M. mulatta is the most appropriate species for this project because of the pathological similarities between human AIDS and simian AIDS induced in the rhesus monkey. Eighteen (18) monkeys will be used in this study in order to obtain data which are statistically significant (see page 3, "c").
f) Surgery:
If the project involves survival surgery, where will the surgery be conducted?
Building: N/A Room:
Who will be the surgeon?
g) Anesthetics, Analgesics, Tranquilizers, Neuromuscular blocking agents:
Post procedural analgesics should be given whenever there is possibility of pain or discomfort that is more than slight or momentary. If postoperative analgesics are not to be given, justify the practice under part (i) below.
Provide the following information about any of these drugs that you intend to use in this project. Under what circumstances will incremental doses of anesthetics-analgesics be administered?
i) Adverse effects:
Describe any potential adverse effects of the experiment on the animals (such as pain, discomfort; reduced growth, fever, anemia, neurological deficits; behavioral abnormalities or other clinical symptoms of acute or chronic distress or nutritional deficiency)
No adverse or side effect, except common discomfort during the venipuncture and injection, is expected to occur; no unusual pain or discomfort is expected for these procedures. Alterations in growth and weight gain, however, will occur. Based upon the data of our previous experiments, as the dependency state is being established, the animals recede food intake and weights plateau. Once the dependency state is fully established, food in-take increases but not back to the predependency state. Other symptoms (diarrhea, etc.) following SIV infection of the animals will be monitored by veterinarian staff.
How will the signs listed above be ameliorated or alleviated? If signs are not to be alleviated or ameliorated by means of post-operative analgesics or other means, explain why this is necessary.
There is nothing in the research protocol that should produce pain or discomfort other than the viremia and sequellae. As with our previous studies, veterinary interaction occurs at anytime with discussion and with notification of the investigators for the use of anesthetics and/or analgesics in a timely fashion.
Note: if any unanticipated adverse effects not described above do occur during the course of the study, a complete description of those effects and the steps taken to mitigate them must be submitted to the committee as an amendment to this protocol.
Is death an endpoint in your experimental procedure? [ ] Yes [ x ] No What were your findings with respect to alternative methodologies?
SIV-infected monkeys are still presently the closest animal model available for the study of human AIDS.
Has this study been previously conducted? [ ] Yes [ x] No
If the study has been conducted previously, explain why it is scientifically necessary to replicate the experiment.
k) Disposition of animals:
At what point in the study, if any, will the animals be euthanized?
We believe that if excessive suffering, extensive disease, and severe weight loss are observed in the animal, veterinary staffs should be consulted for either treatment or euthanasia to be done on the animal. For euthanasia, standard clinical criteria will be utilized by CPRC's experienced veterinarians in consultation with the PIs to determine when the animals will be euthanized. Animals not euthanized at the conclusion of the project will be kept for PIs' next phase of studies with consultation with the veterinary staff. n) Project Roster: Please provide the names of all the individuals who will work with animals on this project. This page will not be made available to the public. Give either the University Employee ID # or a valid UC Davis email address so that we can document training and occupational health compliance for regulatory agencies. Include all investigators, student employees, post-doctoral researchers, staff research associates, post-graduate researchers and laboratory assistants who will actually work with the animals. You don't need to include the staff of the vivarium in which your animals will be housed.
The principal investigator is responsible for keeping this roster current. If any staff is added or subtracted from this project, you must amend the protocol by sending the campus veterinarian a memo describing any changes. SIVmac239 will be used throughout the project. SIVmac239 is a molecular clone of simian immunodeficiency virus (SIV). SIV is a monkey counterpart of human immunodeficiency virus (HIV). SIV causes in monkeys immunodeficiency syndromes in a similar way HIV causes AIDS in human. So far no scientific evidence of AIDS-like diseases may be induced in humans by SIV. In this study, the CPRC standard procedures for SIV handling will be followed.
Last

This agent / material is hazardous for:
[ ] Humans only [ x ] No human disease related to SIVmac239 has ever been described. However, SIV can infect human cells in tissue culture cell lines.
The precautions checked below apply to this experiment:
[ ] The researcher or his/her technicians are responsible for the feeding and care of these animals. [ x ] The following items must be assumed to be contaminated with hazardous material and must be handled only by the researcher or his/her technicians. [ x ] Personal Protective Equipment Required: [x ] The following personal protective equipment must be worn/used in the room: [ x ] Lab Coat/Coveralls [ x ] Shoe Covers/Booties [ x ] Disposable Gloves [ x ] Head Cover
